α-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication S Aulić, L Masperone, J Narkiewicz, E Isopi, E Bistaffa, E Ambrosetti, ... Scientific reports 7 (1), 10050, 2017 | 117 | 2017 |
Defined α-synuclein prion-like molecular assemblies spreading in cell culture S Aulić, TTN Le, F Moda, S Abounit, S Corvaglia, L Casalis, S Gustincich, ... BMC neuroscience 15, 1-12, 2014 | 87 | 2014 |
Role of Rad51 and DNA repair in cancer: A molecular perspective E Laurini, D Marson, A Fermeglia, S Aulic, M Fermeglia, S Pricl Pharmacology & therapeutics 208, 107492, 2020 | 86 | 2020 |
Computational alanine scanning and structural analysis of the SARS-CoV-2 spike protein/angiotensin-converting enzyme 2 complex E Laurini, D Marson, S Aulic, M Fermeglia, S Pricl ACS nano 14 (9), 11821-11830, 2020 | 72 | 2020 |
A fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer’s and Prion diseases M Staderini, S Aulić, M Bartolini, HNA Tran, V González-Ruiz, DI Pérez, ... ACS Medicinal Chemistry Letters 4 (2), 225-229, 2013 | 62 | 2013 |
Small-molecule theranostic probes: a promising future in neurodegenerative diseases S Aulić, ML Bolognesi, G Legname International journal of cell biology 2013, 2013 | 50 | 2013 |
Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies E Laurini, D Marson, S Aulic, A Fermeglia, S Pricl Scientific Reports 11 (1), 20274, 2021 | 39 | 2021 |
Computational mutagenesis at the SARS-CoV-2 spike protein/angiotensin-converting enzyme 2 binding interface: comparison with experimental evidence E Laurini, D Marson, S Aulic, A Fermeglia, S Pricl ACS nano 15 (4), 6929-6948, 2021 | 39 | 2021 |
Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase A Carta, A Bua, P Corona, S Piras, I Briguglio, P Molicotti, S Zanetti, ... European Journal of Medicinal Chemistry 161, 399-415, 2019 | 28 | 2019 |
Synthetic prions with novel strain-specified properties F Moda, TN T. Le, S Aulić, E Bistaffa, I Campagnani, T Virgilio, A Indaco, ... PLoS pathogens 11 (12), e1005354, 2015 | 27 | 2015 |
Synthetic prions and other human neurodegenerative proteinopathies NTT Le, J Narkiewicz, S Aulić, G Salzano, HT Tran, D Scaini, F Moda, ... Virus research 207, 25-37, 2015 | 21 | 2015 |
Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine S Aulic, D Marson, E Laurini, M Fermeglia, S Pricl Nanomedicines for Breast Cancer Theranostics, 371-404, 2020 | 19 | 2020 |
Dichloro-phenyl-benzotriazoles: A new selective class of human respiratory syncytial virus entry inhibitors S Piras, G Sanna, A Carta, P Corona, R Ibba, R Loddo, S Madeddu, ... Frontiers in chemistry 7, 247, 2019 | 16 | 2019 |
9-Aminoacridine-based agents impair the bovine viral diarrhea virus (BVDV) replication targeting the RNA-dependent RNA polymerase (RdRp) R Loddo, V Francesconi, E Laurini, S Boccardo, S Aulic, M Fermeglia, ... Bioorganic & Medicinal Chemistry 26 (4), 855-868, 2018 | 15 | 2018 |
Evolution from covalent to self-assembled PAMAM-based dendrimers as nanovectors for siRNA delivery in cancer by coupled in silico-experimental studies. Part I: Covalent siRNA … D Marson, E Laurini, S Aulic, M Fermeglia, S Pricl Pharmaceutics 11 (7), 351, 2019 | 13 | 2019 |
Multiscale molecular modelling for the design of nanostructured polymer systems: industrial applications M Fermeglia, A Mio, S Aulic, D Marson, E Laurini, S Pricl Molecular Systems Design & Engineering 5 (9), 1447-1476, 2020 | 11 | 2020 |
Evolution from covalent to self-assembled PAMAM-based dendrimers as nanovectors for siRNA delivery in cancer by coupled in silico-experimental studies. Part II: Self-assembled … E Laurini, D Marson, S Aulic, M Fermeglia, S Pricl Pharmaceutics 11 (7), 324, 2019 | 10 | 2019 |
Rational approach to an antiprion compound with a multiple mechanism of action ML Bolognesi, S Bongarzone, S Aulic, HN Ai Tran, F Prati, P Carloni, ... Future Medicinal Chemistry 7 (16), 2113-2120, 2015 | 9 | 2015 |
Molecular and functional characterization of a new 3′ end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant imatinib V Perfetti, E Laurini, S Aulić, M Fermeglia, R Riboni, M Lucioni, E Dallera, ... Oncotarget 8 (34), 56158, 2017 | 8 | 2017 |
Cationic dendrimers for siRNA delivery: an overview of methods for in vitro/in vivo characterization E Laurini, S Aulic, D Marson, M Fermeglia, S Pricl Design and Delivery of SiRNA Therapeutics, 209-244, 2021 | 6 | 2021 |